These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23292811)

  • 1. Ambrisentan reduces pulmonary arterial hypertension but does not stimulate alveolar and vascular development in neonatal rats with hyperoxic lung injury.
    Wagenaar GT; Laghmani el H; de Visser YP; Sengers RM; Steendijk P; Baelde HJ; Walther FJ
    Am J Physiol Lung Cell Mol Physiol; 2013 Feb; 304(4):L264-75. PubMed ID: 23292811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury.
    Wagenaar GT; Laghmani el H; Fidder M; Sengers RM; de Visser YP; de Vries L; Rink R; Roks AJ; Folkerts G; Walther FJ
    Am J Physiol Lung Cell Mol Physiol; 2013 Sep; 305(5):L341-51. PubMed ID: 23812633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats.
    Wagenaar GT; Sengers RM; Laghmani el H; Chen X; Lindeboom MP; Roks AJ; Folkerts G; Walther FJ
    Am J Physiol Lung Cell Mol Physiol; 2014 Aug; 307(3):L261-72. PubMed ID: 24951776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats.
    de Visser YP; Walther FJ; Laghmani el H; Steendijk P; Middeldorp M; van der Laarse A; Wagenaar GT
    Am J Physiol Lung Cell Mol Physiol; 2012 Jan; 302(1):L56-67. PubMed ID: 21949154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apelin attenuates hyperoxic lung and heart injury in neonatal rats.
    Visser YP; Walther FJ; Laghmani el H; Laarse Av; Wagenaar GT
    Am J Respir Crit Care Med; 2010 Nov; 182(10):1239-50. PubMed ID: 20622042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.
    de Visser YP; Walther FJ; Laghmani el H; Boersma H; van der Laarse A; Wagenaar GT
    Respir Res; 2009 Apr; 10(1):30. PubMed ID: 19402887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin attenuates hyperoxia-induced lung injury in neonatal rats by reducing the inflammatory response.
    Chen X; Walther FJ; Sengers RM; Laghmani el H; Salam A; Folkerts G; Pera T; Wagenaar GT
    Am J Physiol Lung Cell Mol Physiol; 2015 Aug; 309(3):L262-70. PubMed ID: 26047641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambrisentan: a review of its use in pulmonary arterial hypertension.
    Rivera-Lebron BN; Risbano MG
    Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of NO-cGMP signaling by neonatal hyperoxia impairs relaxation of lung parenchyma.
    Sopi RB; Haxhiu MA; Martin RJ; Dreshaj IA; Kamath S; Zaidi SI
    Am J Physiol Lung Cell Mol Physiol; 2007 Oct; 293(4):L1029-36. PubMed ID: 17660329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of ambrisentan in the management of pulmonary hypertension.
    Hrometz SL; Shields KM
    Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled nitric oxide improves lung structure and pulmonary hypertension in a model of bleomycin-induced bronchopulmonary dysplasia in neonatal rats.
    Tourneux P; Markham N; Seedorf G; Balasubramaniam V; Abman SH
    Am J Physiol Lung Cell Mol Physiol; 2009 Dec; 297(6):L1103-11. PubMed ID: 19837849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
    Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
    Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).
    Maron BA; Waxman AB; Opotowsky AR; Gillies H; Blair C; Aghamohammadzadeh R; Loscalzo J; Leopold JA
    Am J Cardiol; 2013 Sep; 112(5):720-5. PubMed ID: 23751938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
    Vizza CD; Fedele F; Pezzuto B; Rubin LJ
    Expert Opin Drug Saf; 2012 Nov; 11(6):1003-11. PubMed ID: 22861496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-citrulline attenuates arrested alveolar growth and pulmonary hypertension in oxygen-induced lung injury in newborn rats.
    Vadivel A; Aschner JL; Rey-Parra GJ; Magarik J; Zeng H; Summar M; Eaton F; Thébaud B
    Pediatr Res; 2010 Dec; 68(6):519-25. PubMed ID: 20805789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Right ventricular cyclic nucleotide signaling is decreased in hyperoxia-induced pulmonary hypertension in neonatal mice.
    Heilman RP; Lagoski MB; Lee KJ; Taylor JM; Kim GA; Berkelhamer SK; Steinhorn RH; Farrow KN
    Am J Physiol Heart Circ Physiol; 2015 Jun; 308(12):H1575-82. PubMed ID: 25862831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
    Takatsuki S; Rosenzweig EB; Zuckerman W; Brady D; Calderbank M; Ivy DD
    Pediatr Pulmonol; 2013 Jan; 48(1):27-34. PubMed ID: 22511577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
    Yoshida S; Shirato K; Shimamura R; Iwase T; Aoyagi N; Nakajima H
    Curr Med Res Opin; 2012 Jun; 28(6):1069-76. PubMed ID: 22506623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of pulmonary arterial hypertension: role of ambrisentan.
    Barst RJ
    Vasc Health Risk Manag; 2007; 3(1):11-22. PubMed ID: 17583171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic evaluation of ambrisentan.
    Buckley MS; Wicks LM; Staib RL; Kirejczyk AK; Varker AS; Gibson JJ; Feldman JP
    Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):371-80. PubMed ID: 21299444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.